|
1.1 Biologie - Gènes
|
|
|
|
2. Etiologie
|
|
|
Well: Wondering What Caused the Cancer [NY Times]
|
|
|
|
|
|
Dozens
of my patients have asked the same thing. Even a dozen dozen. I think
the question reflects a human desire to revisit events that occurred
over a lifetime, and speculate whether a change in course could have
avoided an untoward outcome.
|
|
|
|
|
|
|
3.3 Prévention - Vaccins
|
|
|
Ontario to offer HPV vaccine to boys [The Globe & Mail]
|
|
|
|
|
|
Dr.
Hoskins said the province is also moving the program up a year, meaning
all Ontario students will now be offered the vaccine in Gr. 7 instead
of Gr. 8. The change is being done, in part, to save money by bundling
the HPV vaccine with other needles given to students in that school
year.
|
|
|
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
|
5.12 Immunothérapies
|
|
|
|
A Biotech Billionaire's Cancer 'Moonshot' [Medscape]
|
|
|
|
|
|
My
view of the next-generation therapy is to take this high-dose
standard-of-care chemotherapy and reduce it to low-dose chemotherapy
given in the outpatient setting. Then, we engage in hand-to-hand combat
with the cancer cells in real time with the dendritic cell, the natural
killer cell, the T cell, and the suppressor cell.
|
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
NICE success for Sanofi's Jevtana after re-appraisal [Pharma Times]
|
|
|
|
|
|
Between
2013 and 2015, over 550 patients accessed Jevtana (as a second-line
treatment after docetaxel) through the Cancer Drugs Fund. Now, with this
positive recommendation from NICE, the drug will move out of the CDF
and into routine use, although the number of patients accessing it is
not anticipated to change as a result.
|
|
|
|
|
|
|
NICE recommends cabazitaxel for prostate cancer [NICE]
|
|
|
|
|
|
After
the medicine was turned down, Sanofi increased the discount and
confirmed that it can supply cabazitaxel in intravenous bags instead of
vials, reducing waste. Therefore, they have concluded that cabazitaxel
is a cost-effective treatment option.
|
|
|
|
|
|
|
|
5.9 AACR
|
|
|
|
|
5.9.5 AACR - T-cell immunothérapies
|
|
|
|
6.10 Politiques
|
|
|
|
6.11 Patients
|
|
|
Why people keep quiet about their battle with cancer [BBC News]
|
|
|
|
|
|
Close
friends and family of Victoria Wood have spoken of their shock at
finding out the comedian was suffering from cancer. Her brother said
when it came to her final illness she was "determined" not to let the
news leak out - even to relatives and loved ones. So why do some people
choose to keep quiet about their battle?
|
|
|
|
|
|
|
6.6 Publications
|
|
|
Want a favorable peer review? Buy one [STAT]
|
|
|
|
|
|
Last
year, BioMed Central retracted 43 papers for fake reviews, some of
which appeared to have been conducted by “third-party agencies,” the
publisher said. In 2014, SAGE said that it had uncovered a peer review
“ring,” orchestrated by Taiwanese scientist Peter Chen, which led to the
retraction of 60 papers.
|
|
|
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
Data sharing review delayed [PHG Foundation]
|
|
|
|
|
|
The
long-awaited data sharing review from the National Data Guardian, Dame
Fiona Caldicott is complete but will not be published until after the EU
referendum. Commissioned by Jeremy Hunt in September 2015, the review
will provide guidance on a new consent and opt-out model for the sharing
of patient information and data security in the NHS.
|
|
|
|
|
|
FDA’s Foray Into Big Data Still Maturing [JAMA]
|
|
|
|
|
|
“It’s
a good thing that FDA has invested heavily in learning what we can do
with electronic health records at the present time,” Moore said.
“Unfortunately, the lesson is not nearly as much as we’d hoped.”
|
|
|
|
|
|
|
|
|
6.8 Communication
|
|
|
The Cancer Lifestyle Check – a missed opportunity? [Croakey]
|
|
|
|
|
|
It
sounds straightforward but how accurate are the claims being made by
the Government and Cancer Australia about this online resource? Given
our current understanding of the impact of the social determinants of
health, including pervasive factors such as poverty and racism, how
accurate is it to categorise some cancer risks as ‘lifestyle factors’?
|
|
|
|
|
|
|